Actively Recruiting
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Led by Canadian Cancer Trials Group · Updated on 2026-05-12
60
Participants Needed
7
Research Sites
243 weeks
Total Duration
On this page
Sponsors
C
Canadian Cancer Trials Group
Lead Sponsor
C
Cancer Research Institute, New York City
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
CONDITIONS
Official Title
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women with platinum resistant high grade serous ovarian, fallopian tube, or peritoneal carcinoma
- Disease progression within 6 months of last platinum chemotherapy
- Measurable disease by RECIST 1.1 criteria
- At least one disease site suitable for pre and on-treatment biopsies
- At least 28 days since any major surgery with healed wounds
- No more than one prior cytotoxic chemotherapy regimen for platinum-resistant disease
- Prior immune checkpoint inhibitor allowed if discontinued without severe toxicity
- Minimum 4 weeks since last therapy with recovery from toxicity to grade 1 or less
- Radiation, endocrine, or non-anti-cancer investigational agents allowed with 28 day gap
- ECOG performance status 0 or 1 and life expectancy 3 months or more
- Age 18 years or older
- Consent for tumor tissue release and biopsies
- Willing and able to comply with study visits, treatment, and tests
- Adequate organ and marrow function within 7 days prior to enrollment
- Signed informed consent
- Accessible for treatment and follow-up at participating center
- Protocol treatment to begin within 2 working days of enrollment
- Negative pregnancy test for women of childbearing potential
You will not qualify if you...
- History of other malignancies affecting safety or efficacy unless curatively treated
- Uncontrolled or serious illnesses posing safety risks, including recent intra-abdominal abscess, active infections, HIV, hepatitis B or C with detectable viral load
- History of interstitial lung disease or severe pulmonary disease
- Significant pleural, pericardial, or peritoneal effusions requiring intervention
- Autoimmune diseases requiring chronic steroids
- Stroke or transient ischemic attack within 6 months
- Significant cardiac disease within 6 months
- Prior allogeneic stem cell or organ transplantation
- Central nervous system metastases that are symptomatic or uncontrolled
- Pregnant or breastfeeding women
- Concurrent treatment with other anti-cancer or investigational agents
- Active or recent autoimmune or inflammatory disorders within past 3 years, except select low-risk conditions
- Live vaccine administration within 4 weeks prior to enrollment
- QTc interval above specified thresholds or with additional risk factors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
The University of Chicago Medical Center
Chicago, Illinois, United States, 60637
Actively Recruiting
2
BCCA - Kelowna
Kelowna, British Columbia, Canada, V1Y 5L3
Not Yet Recruiting
3
BCCA - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6
Not Yet Recruiting
4
Odette Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
Not Yet Recruiting
5
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Not Yet Recruiting
6
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2X 3E4
Not Yet Recruiting
7
The Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Not Yet Recruiting
Research Team
J
Janet Dancey
CONTACT
P
Pierre-Olivier Gaudreau
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here